TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

250 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

136 studies on the map

Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Research Site, Birmingham5-HTP and Creatine for Depression R33 Phase — University of Utah Department of Psychiatry, Salt Lake CityAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New HavenPhase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments — Domino's Farms, Ann ArborVirtual tES Device Treatment for Parkinson's Disease Motor Symptoms — U LLC Headquarters, ClevelandA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenStudy of ALTO-300 in MDD — Site 200, PhoenixPersonalized Brain Stimulation to Treat Chronic Concussive Symptoms — UCLA, Westwood, Los AngelesClinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis — Johns Hopkins, BaltimoreKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CityA Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease — Banner Sun Health Research Institute, Sun CityA Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery — University of Kentucky, LexingtonDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder — Collaborative Neuroscience Network, Garden GroveEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamA Study of Buntanetap in Participants With PD — University of Alabama at Birmingham, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamPET Imaging Evaluation of [11C]SY08 — MGH, CharlestownPsilocybin rTMS for Treatment Resistant Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleCognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Massachusetts General Hospital, BostonSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceEvaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies — Institute for Neurodegenerative Disorders and XingImaging, LLC, New HavenAllopregnanolone (Zuranolone) in Post-stroke Depression — Duke South Neurology Clinic 1L, DurhamLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisTo Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — DM Clinical Research - Phoenix, PhoenixPilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine — University of Pennsylvania, PhiladelphiaStratified Pharmacological Approaches for Regulating Circuit-Level Effects — Stanford University, Palo AltoDBS for Depression — Zucker Hillside Hospital, QueensArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaAdjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression — The University of Texas Health Science Center at Houston, HoustonOpen-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease — Invicro (dba Perceptive), New HavenNeutralizing Interleukin (IL)-6 — Icahn School of Medicine at Mount Sinai, New YorkRegulation of Affect and Physiology in Depression — University of Southern California, Los AngelesA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisPharmacologic Augmentation of TMS for Depression With D-serine — McLean Hospital, BelmontApimostinel + Automated Neurocognitive Training for Depression — Western Psychiatric Institute and Clinic, PittsburghImaging Depression in Parkinson's Disease — Yale University, New HavenA Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease — Collaborative Neuroscience Network - CNS, Los AlamitosBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraKetamine for Veterans With Parkinson's Disease — San Francisco VA Medical Center, San Francisco, CA, San FranciscoPsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, TulsaKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborProbiotic Administration for Adolescent Depression — UCSF, San FranciscoSAD Study in Patients With Parkinson's Disease and Motor Fluctuations — Rocky Mountain Clinical Research, EnglewoodTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonEarly Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging) — Institute for Neurodegenerative Disorders, New HavenOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenA Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression — UCLA Semel Institute - Neuropsychiatric Institute (NPI), Los AngelesPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixPsilocybin-Assisted Therapy for Intergenerational Trauma — The Parsons Research Center for Psychedelic Healing, New YorkCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los AngelesRademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — University of Alabama at Birmingham Lung Health Center, BirminghamA Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) — Equity Medical Bowling Green, Bowling GreenEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxConfirmatory Efficacy Trial of Attention Bias Modification for Depression — Institute for Mental Health Research, AustinZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisEvaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression — Laureate Institute for Brain Research, TulsaAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraInvestigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — National Institutes of Health Clinical Center, BethesdaPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoA Pilot Study of In-lab Dynamic Standing in Parkinson's Disease — Domino's Farms, Ann ArborLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsFirst-in-Human Single and Multiple Dose of HL-400 — Pharmaron CPC, Inc., BaltimoreA Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) — Mayo Clinic, PhoenixModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamLow-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease — Quest Research Institute, Farmington HillsALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New YorkUsing taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease — Wellness, Health and Research Facility at UAB, BirminghamA Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — SEC Clinical Research, LLC, DothanCannabidiol and Older Adult Cannabis Users — University of Colorado at Boulder, BoulderNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonLongitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging) — UAB, BirminghamPyridostigmine for the Treatment of Constipation in Parkinson Disease — University of Vermont Medical Center, BurlingtonMood Effects of Serotonin Agonists: Depression — University of Chicago, ChicagoFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, ColumbusPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityPsilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder — Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New YorkThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — VA Connecticut Healthcare System, West HavenEnrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. — UPMC Presbyterian Hospital, PittsburghA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoRehabilitation of Airway Protection in Parkinson's Disease — Purdue University, West LafayetteA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaMindfulness-based Psilocybin Therapy for PTSD — The Ohio State University Medical Center, ColumbusA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — University of Alabama at Birmingham Lung Health Center, BirminghamGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies — Fred Hutch/University of Washington Cancer Consortium, SeattleA Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease — University of Alabama at Birmingham, BirminghamA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Study to Evaluate Solrikitug in Participants With COPD (ZION) — University of Alabama at Birmingham Hospital, BirminghamDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonThis Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. — Cornell University Weill Medical College, New YorkTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin — University of Illinois Chicago, Sickle Cell Center, ChicagoPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, Phoenix18F-mFBG Cardiac Uptake With Lewy Body Dementia — Houston Methodist Neurological Institute, HoustonSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression — Draig Clinical Site, DeSotoTenapanor in Synucleinopathy-Related Constipation — Cedar Valley Digestive Health Center, WaterlooEvaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease — Institute for Neurodegenerative Disorders / XingImaging, LLC, New HavenA Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations — University of Arkansas for Medical Sciences, Little RockSubanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients — Mayo Clinic, JacksonvilleSleep to Reduce Incident Depression Effectively in Peripartum — Henry Ford Medical Center, NoviSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkA Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) — WB Contracted Clinical Research Site, Miami LakesGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression — Wells Medicine, Houston

Showing the 150 nearest — narrow your filters for fewer, closer studies.